LOGIN  |  REGISTER
Cue Biopharma

Clover Health to Present at Canaccord Genuity 43rd Annual Growth Conference and 2023 Wells Fargo Healthcare Conference

August 02, 2023 | Last Trade: US$3.35 0.07 2.13

FRANKLIN, Tenn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement company committed to improving health equity for seniors, today announced its participation in the following investor conferences:

  • CEO, Andrew Toy, will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 8:00 a.m. Eastern Time.
  • CFO, Scott J. Leffler, will present at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6, 2023, at 10:15 a.m. Eastern Time.

A live webcast and reply of the presentations will be accessible from Clover Health's investor relations website at https://investors.cloverhealth.com/.

About Clover Health

Clover Health (Nasdaq: CLOV) is a physician enablement company committed to bringing access to great healthcare to everyone on Medicare. This includes a health equity-based focus on seniors who have historically lacked access to affordable, high-quality healthcare. Our strategy is powered by our software platform, Clover Assistant, which is designed to aggregate patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic disease. We operate two distinct lines of business: Insurance and Non-Insurance. Through our Insurance line of business, we provide PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on our flagship wide-network, high-choice PPO plans. Our Non-Insurance line of business similarly aims to reduce cost-of-care while enhancing the quality of care for patients enrolled in Original Medicare.

Press Contact:
Andrew Still-Baxter
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations Contact:
Ryan Schmidt
This email address is being protected from spambots. You need JavaScript enabled to view it.

C4 Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB